PCM
SRDX

Perkins Capital Management’s Surmodics SRDX Stock Holding History

Perkins Capital Management’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-36,450
Closed -$926K – 115
2016
Q4 		$926K Sell
36,450
-7,300
-17% -$192K 1.02% 33
2016
Q3 		$1.32M Buy
+43,750
New +$1.2M 1.32% 19

Other funds holding SRDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TA
Teton Advisors Rye, New York $173M AUM 77.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perkins Capital Management's SRDX Position: Q1 2017 in Review

Perkins Capital Management sold out of Surmodics (SRDX) in Q1 2017, closing a stake of 36,450 shares — an estimated $926K sold.

Perkins Capital Management first reported a position in SRDX in Q3 2016 and held it in 2 quarters. The position peaked at $1.32M in Q3 2016. 111 funds tracked by Wall St. Rank hold SRDX as of Q1 2017.

  • Perkins Capital Management reported no remaining Surmodics position as of Q1 2017 after selling out during the quarter.
  • Perkins Capital Management sold 36,450 Surmodics shares in Q1 2017, an estimated $926K.
  • Perkins Capital Management first reported a position in Surmodics in Q3 2016 and held it in 2 quarters.
  • Perkins Capital Management's Surmodics position peaked at $1.32M in Q3 2016.
  • 111 funds tracked by Wall St. Rank held Surmodics as of Q1 2017.

Based on Perkins Capital Management's 13F filing for Q1 2017, filed 19 Apr 2017.